SCHEMBL1899659

SCHEMBL1899659

O=C1C=NC2=Nc3ccccc3C2=N1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.37
LMNA P02545 4/20 0.37
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
APAF1 O14727 1/20 0.37
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
TSHR P16473 1/20 0.37
HK1 P19367 1/20 0.37
GALK1 P51570 1/20 0.37
HKDC1 Q2TB90 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
IDO1 P14902 1/20 0.34
SRC P12931 2/20 0.33
CTRB1 P17538 2/20 0.33
CCNE1 P24864 2/20 0.33
CDK2 P24941 2/20 0.33
AHR P35869 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL536721 0.68 MAPT (0.38) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL30997931 0.68 MAPT (0.38) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL8618626 0.68 NOTUM (0.39) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL8623122 0.68 CYP2A6 (0.39) MAPTLMNAALDH1A1L3MBTL1IDO1
SCHEMBL4515365 0.67 IDO1 (0.54) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL8690288 0.66 MEN1 (0.59) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL643335 0.66 MAPT (0.37) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL1898381 0.66 ABCG2 (0.37) CDC25B
SCHEMBL8620821 0.65
SCHEMBL21316073 0.65 MEN1 (0.63) MAPTLMNAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117756761-B Benzofuranone derivative and preparation method thereof 酒泉亚佳化学有限公司 2024-06-21 CN claimed
CN-117756761-A Benzofuranone derivative and preparation method thereof 酒泉亚佳化学有限公司 2024-03-26 CN claimed
US-20040204347-A1 Treatment of demyelinating disorders EISAI CO., LTD. (JP) 2004-10-14 US claimed
US-6797692-B1 Use of glutamate antagonists for the treatment of cancer IKONOMIDOU HRISSANTHI (DE) 2004-09-28 US claimed
JP-2002519373-A 2002-07-02 JP claimed
EP-1124553-A1 NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER Ikonomidou, Hrissanthi (DE) 2001-08-22 EP claimed
EP-1100504-A2 PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS Eisai Co., Ltd. (JP) 2001-05-23 EP claimed
EP-1002535-A1 New use of glutamate antagonists for the treatment of cancer Ikonomidou, Hrissanthi (DE) 2000-05-24 EP claimed
WO-2000024395-A1 NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER IKONOMIDOU HRISSANTHI (DE) 2000-05-04 WO claimed
WO-2000001376-A2 PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS EISAI CO., LTD (JP) 2000-01-13 WO claimed
CN-117756761-B Benzofuranone derivative and preparation method thereof 酒泉亚佳化学有限公司 2024-06-21 CN disclosed
CN-117756761-B Benzofuranone derivative and preparation method thereof 酒泉亚佳化学有限公司 2024-06-21 CN disclosed
CN-117756761-A Benzofuranone derivative and preparation method thereof 酒泉亚佳化学有限公司 2024-03-26 CN disclosed
CN-117756761-A Benzofuranone derivative and preparation method thereof 酒泉亚佳化学有限公司 2024-03-26 CN disclosed
US-20130281523-A1 LOW DOSE CANNABINOID MEDICAMENTS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2013-10-24 US disclosed
EP-1124553-A1 NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER Ikonomidou, Hrissanthi (DE) 2001-08-22 EP disclosed
EP-1100504-A2 PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS Eisai Co., Ltd. (JP) 2001-05-23 EP disclosed
EP-1002535-A1 New use of glutamate antagonists for the treatment of cancer Ikonomidou, Hrissanthi (DE) 2000-05-24 EP disclosed
WO-2000024395-A1 NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER IKONOMIDOU HRISSANTHI (DE) 2000-05-04 WO disclosed
WO-2000001376-A2 PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS EISAI CO., LTD (JP) 2000-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204347-A1 Treatment of demyelinating disorders GRIK4, GRIK5, PMP22 MAPT 619/4885LMNA 3834/4885MEN1 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.